Plain-English translation of NCT07003737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , an immune-boosting medication that helps your own T cells fight cancer, can improve long-term survival when given before a stem cell transplant. You would be randomly assigned to either receive this medication before your transplant or to proceed directly to transplant without it. The study is looking at whether the medication helps prevent the cancer from coming back.
Even when patients achieve remission from this aggressive blood cancer, the disease can return after transplant. This study explores whether giving this medication as an extra boost before transplant can strengthen the immune system's ability to stay on guard and prevent relapse long-term.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups: one group will receive the medication as an infusion before undergoing the stem cell transplant, while the other group will proceed straight to transplant. You will have regular blood tests, scans, and doctor visits to monitor how you respond, both during the medication phase (if assigned to that group) and after your transplant. The study will follow you for an extended period to see whether the medication helps prevent your cancer from returning.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China